Levels of microparticle tissue factor activity correlate with coagulation activation in endotoxemic mice by WANG, J.-G. et al.
Levels of microparticle tissue factor activity correlate with
coagulation activation in endotoxemic mice
J.-G. WANG*, D MANLY*, D KIRCHHOFER†, R PAWLINSKI*, and N MACKMAN*
*Division of Hematology/Oncology, Department of Medicine, University of North Carolina at Chapel
Hill, Chapel Hill, NC
†Department of Protein Engineering, Genentech, Inc., South San Francisco, CA, USA
Summary
Background—Tissue factor (TF) is present in blood in various forms, including small membrane
vesicles called microparticles (MPs). Elevated levels of these MPs appear to play a role in the
pathogenesis of thrombosis in a variety of diseases, including sepsis.
Objective—Measure levels of MP TF activity and activation of coagulation in control and
endotoxemic mice.
Materials and methods—MPs were prepared from plasma by centrifugation. The procoagulant
activity (PCA) of MPs was measured using a two-stage chromogenic assay. We also measured levels
of thrombin-antithrombin and the number of MPs.
Results—Lipopolysaccharide (LPS) increased MP PCA in wild-type mice; this PCA was
significantly reduced by an anti-mouse TF antibody (1H1) but not with an anti-human TF antibody
(HTF-1). Conversely, in mice expressing only human TF, MP PCA was inhibited by HTF-1 but not
1H1. MPs from wild-type mice had 6-fold higher levels of PCA using mouse factor (F)VIIa compared
with human FVIIa, which is consistent with reported species-specific differences in FVIIa. Mice
expressing low levels of human TF had significantly lower levels of MP TF activity and TAT than
mice expressing high levels of human TF; however, there were similar levels of phosphatidylserine
(PS)-positive MPs. Importantly, levels of MP TF activity in wild-type mice correlated with levels of
TAT but not with PS-positive MPs in endotoxemic mice.
Conclusion—These results suggest that the levels of TF-positive MPs can be used as a biomarker
for evaluating the risk of disseminated intravascular coagulation in endotoxemia.
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Tissue factor (TF) within the vessel wall plays a critical role in hemostasis by activating the
clotting cascade after vessel injury [1]. TF is also present in plasma in various forms, including
microparticles (MPs) and alternatively spliced TF [2,3]. MPs are small (< 1 µm) membrane
vesicles generated by activated or apoptotic cells [4]. Levels of TF-positive MPs are elevated
in a variety of diseases, such as sepsis, cardiovascular disease, sickle cell disease and cancer
[5–11]. One study showed that TF-positive MPs from pericardial blood of cardiac surgery
patients enhanced venous thrombosis in a rat model [10]. In healthy mice, hematopoietic cell-
derived TF-positive MPs enhance thrombosis in cremaster muscle arterioles of mice [12]. In
tumor-bearing mice, levels of human TF antigen in plasma correlated with the size of the tumor,
and increased levels of tumor-derived MPs were associated with increased levels of thrombin-
antithrombin (TAT) complex [13,14]. These studies strongly suggest that TF-positive MPs
contribute to thrombosis in many diseases.
TF expression contributes to disseminated intravascular coagulation in a baboon model of
sepsis [15]. Monocytes appear to be the major source of TF within the circulation [1,16].
Indeed, LPS stimulation of monocytes induces TF mRNA and protein expression in monocytes
in a human model of endotoxemia [17,18]. Moreover, we have shown that reducing levels of
TF expression in hematopoietic cells is associated with a reduction in TAT levels in
endotoxemic mice [19]. TF expression by other cell types, such as endothelial cells, may also
contribute to intravascular coagulation [1].
Levels of TF in human plasma can be measured using various methods, including enzyme-
linked immunosorbent assays (ELISA), flow cytometry, an impedance assay and activity
assays [9,20–24]. A wide range of TF antigen levels have been reported in healthy individuals,
which appears to be due to the use of different anti-TF antibodies and the relatively high
background associated with the commercial ELISA called IMUBIND® [25]. A commercial
assay called ACTI-CHROME ® can be used to measure factor (F)Xa generation in plasma
[22,26]. However, a recent study indicated that this assay did not measure TF activity in plasma
because the observed FXa generation was not inhibited by active site inactivated FVIIa [27].
An alternative strategy is to isolate MPs from the plasma and assay their PCA. MPs can be
collected by either capturing the MPs with a specific antibody called 1B10 [7] or by isolating
the MPs by centrifugation [23,28]. In these assays, the procoagulant activity (PCA) is measured
using a two-stage chromogenic activity assay in the presence and absence of an inhibitory anti-
human TF antibody.
Human TF antigen and activity can be measured in plasma from mice bearing human tumors
or in mice expressing human TF in place of mouse TF [13,14,19]. One study showed a human
TF-dependent increase in thrombin generation in cell-free plasma from mice bearing human
pancreatic tumors [14]. There have been several papers describing the measurement of PCA
in mouse plasma or in isolated MPs from mice [29–31]. However, a limitation of these studies
is that they did not use an anti-mouse TF antibody to determine the level of TF-dependent vs.
TF-independent activity in the assays. In this study, we used an endotoxemia model to generate
TF-positive MPs in various mice and compare the levels of MP TF activity with TAT complex.
Materials and methods
Materials
Lipopolysaccharide (LPS) (Escherichia coli serotype O111:B4), mouse IgG and rat IgG were
obtained from Sigma-Aldrich (St Louis, MO, USA). Human FVIIa and human FX were
purchased from Enzyme Research Laboratories (South Bend, IN, USA). Purified recombinant
annexin V was purchased from BD Pharmingen™ (San Jose, CA, USA). Inactivated human
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recombinant FVIIa (FVIIai) was purchased from American Diagnostica (Stamford, CT, USA).
Mouse FVIIa was kindly provided by Dr Lars Petersen (Novo Nordisk, Bagsvaerd, Denmark)
[32]. Mouse FVIIa was subjected to the same tests as human FVIIa and has a comparable purity
(Dr Lars Petersen, personal communication). A rat anti-mouse TF monoclonal antibody (1H1)
was provided by Genentech Inc. (South San Francisco, CA, USA) [33]. A mouse anti-human
TF monoclonal antibody (HTF-1) was kindly provided by Dr Ronald Bach (VAMC,
Minneapolis, MN, USA) [34]. FXa substrate (Pefachrome FXa 8595) was obtained from
Centerchem, Inc (Norwalk, CT, USA). Human recombinant relipidated TF (Dade Innovin) and
Enzygnost TAT micro ELISA kit were purchased from Dade Behring (Marburg, Germany).
Mouse endotoxemia model
All studies were approved by the University of North Carolina-Chapel Hill Animal Care and
Use Committee and comply with National Institute of Health guidelines. Wild-type mice
(C57BL/6J) were purchased from The Jackson Laboratory (Bar Harbor, ME, USA). Human
chromosome vector (HTF) mice (~100% of wild-type TF levels except in the heart) and low
TF mice (~1% of wild-type TF mice) were used in this study [35,36]. Mice (2–3 months old)
were injected intraperitoneally with either LPS (7.5 mg kg−1) or saline. Six hours after LPS
injection, whole blood was collected from the inferior vena cava into sodium citrate (final
concentration: 0.38%). Mouse plasma was prepared by centrifugation at 4000 g for 15 min.
Plasma was divided into 50-µL aliquots and frozen at −80 °C.
MP TF activity assay
50 µL of mouse plasma was diluted with 1 mL of HBSA (137 mM NaCl, 5.38 mM KCl, 5.55
mM glucose, 10 mM HEPES, 0.1% bovine serum albumin, pH 7.5) and MPs were pelleted at 20
000 g for 30 min at 4 °C, washed once with 1 mL of HBSA and re-suspended in 100 µL HBSA.
Samples (50 µL each) were then incubated with the rat inhibitory anti-mouse TF antibody
(1H1) (100 µg mL−1), the mouse anti-human TF antibody (HTF-1) (10 µg mL−1) or IgG
controls for 15 min at room temperature. Human FVIIai and annexin V were used in some
experiments. Next, 50µL of HBSA containing 10 nM human FVIIa, 300 nM FX and 10 mM
CaCl2 was added to the sample and incubated for 2 h at 37 °C in a 96-well plate. Mouse FVIIa
was used in some experiments. FXa generation was stopped by the addition of 25 µL of 25
mM EDTA buffer. Finally, 25 µL of the chromogenic substrate Pefachrome FXa 8595 (4 mM)
was added and the mixture incubated at 37 °C for 15 min. Absorbance at 405 nm was measured
using a VERSAmax microplate reader (Molecular Devices). The PCA of the sample was
calculated by reference to a standard curve generated using recombinant human relipidated TF
(0–14 pg mL−1). The TF-dependent PCA generation (pg mL−1) was determined by subtracting
the amount of PCA generated in the presence of blocking antibodies from the amount of total
PCA generated in the presence of the IgG controls.
Measurement of MPs
Phosphatidlyserine (PS)-positive MPs in mouse plasma were detected using a Zymuphen MP-
activity kit (Hyphen BioMed, Neuville-sur-Oise, France) and expressed as PS equivalents
(nM).
Statistical analysis
Data are expressed as mean ± standard deviation (SD). Differences between different groups
were analyzed using a one-tailed heteroscedastic Student’s t-test and a one-way ANOVA. A
probability value P < 0.05 was considered statistically significant. Correlation between MP TF
activity and TAT was analyzed using Spearman’s rho and correlation was significant at the
0.01 level (two-tailed).
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Measurement of MP TF activity in plasma from control and endotoxemic wild-type mice
We chose a mouse endotoxemia model in which LPS (7.5 mg kg−1) was administered via a
single intraperitoneal injection. In the first series of experiments, MP PCA was measured using
mouse FVIIa and human FX in the presence of either the anti-mouse TF antibody 1H1 or rat
IgG. We observed a low baseline of MP PCA in plasma from PBS-treated mice that was
significantly reduced by 1H1 (Fig. 1A). Administration of LPS increased the level of MP PCA,
which was significantly reduced by 1H1 (Fig. 1A). Endotoxemic mice had increased levels of
MP TF activity compared with controls (Fig. 1B). Furthermore, we found increased levels of
TAT and PS-positive MPs in the plasma from LPS-treated mice compared with control mice
(Fig. 1C,D).
Measurement of MP PCA in wild-type mice using mouse FVIIa vs. human FVIIa
We measured the level of PCA in MPs from wild-type mice using either mouse FVIIa or human
FVIIa. As expected, we detected significantly higher levels of MP PCA in control and LPS-
treated mice using mouse FVIIa compared with human FVIIa (Fig. 2). Use of mouse FVIIa
was associated with a 6-fold increase in MP PCA.
Use of species-specific anti-TF antibodies to measure TF activity in MP from mice expressing
mouse or human TF
We used species-specific inhibitory antibodies against either mouse TF (1H1) or human TF
(HTF-1) to distinguish between mouse and human TF activity in MPs from wild-type mice
and mice expressing human TF (HTF mice). Human FVIIa was used in these studies. The PCA
of MPs from wild-type mice with or without LPS was significantly reduced by 1H1 but not by
HTF-1, indicating that the PCA was due to mouse TF (Fig. 3A,B). Conversely, the PCA of
MPs from HTF mice with or without LPS was inhibited by HTF-1 but not 1H1, indicating that
the PCA was due to human TF (Fig. 3C,D). These results indicate that species-specific
antibodies can be used to measure mouse and human TF-dependent PCA in MPs derived from
genetically modified mice.
Inhibition of MP PCA using human FVIIai and annexin V
We determined the effect of human FVIIai on the MP PCA isolated from wild-type and HTF
mice. As expected, human FVIIai was a more potent inhibitor of PCA of MPs from HTF mice
compared with the PCA of MPs from wild-type mice (Fig. 4A,B). We also examined the effect
of annexin V on MP PCA. Annexin V has been shown to reduce the activity of relipidated TF
by binding to the anionic phospholipid PS [37]. We found that annexin V partially inhibited
the PCA of MPs from both wild-type and HTF mice.
Levels of MP TF activity correlate with levels of TAT in endotoxemic mice
We and others have used plasma TAT levels to measure the activation of coagulation in mice
[19,38]. First, we analyzed the levels of MP PCA, MP TF activity and TAT in mice expressing
high (HTF) and low (low TF) levels of human TF. Low TF mice expressed significantly lower
levels of MP PCA, MP TF activity and TAT compared with HTF mice (Fig. 5A–C). However,
low TF and HTF mice had similar levels of PS-positive MPs (Fig. 5D). Second, we compared
the levels of MP TF activity and TAT in wild-type mice. Importantly, we found that there was
a strong correlation between MP TF activity and TAT levels in endotoxemic wild-type mice
(Fig. 6). No correlation was found between PS-positive MPs and TAT (data not shown). Levels
of MP TF activity also correlated with TAT in mice expressing human TF (data not shown).
These results indicate that the presence of TF-positive MPs is a better predictive marker of
activation of the clotting cascade than PS-positive MPs.
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TF-bearing MPs appear to play a role in thrombotic complication associated with a variety of
diseases, including sepsis and cancer [5–11]. As mice are the most common laboratory animals
used for in vivo experiments, we developed an assay to measure levels of circulating TF-
positive MPs in mice. We found that administration of LPS increased the level of MP TF
activity in wild-type mice. In addition, MP TF activity was significantly higher in endotoxemic
mice expressing high levels of human TF compared with mice expressing low levels of human
TF. However, the number of circulating PS-positive MPs was the same in these two groups of
mice. Importantly, we observed a significant linear correlation between MP TF activity and
TAT in endotoxemic wild-type mice (R = 0.78, P < 0.01, n = 16). A previous study showed a
similar correlation between levels of human TF antigen and TAT in plasma from mice bearing
human pancreatic tumors [14]. These data strongly suggest that MP TF activates coagulation
in mouse models of endotoxemia and cancer.
Previous studies measuring PCA in mouse plasma or in isolated MPs from wild-type mice used
a two-stage assay with human FVIIa and human FX [29,31]. However, these studies could not
distinguish between TF-dependent and TF-independent activity because an inhibitory anti-
mouse TF antibody was not used. To date, a major limitation in measuring mouse TF activity
has been the lack of an inhibitory anti-mouse TF antibody. Importantly, the rat anti-mouse TF
antibody called 1H1 was shown to inhibit mouse TF activity [33]. It has been used in two
studies in mice to show that TF plays a role in inflammation in a colitis model and in
antiphospholipid antibody-induced fetal loss [39,40]. We found that 1H1 and HTF-1 inhibited
the majority of the PCA of MP in endotoxemic wild-type mice and HTF mice. The residual
PCA could be due to either incomplete blocking of TF activity or low levels of TF-independent
PCA. As expected, human FVIIai was a more potent inhibitor of the PCA of MPs isolated from
endotoxemic HTF mice than the PCA of MPs from wild-type mice. Annexin V also partially
inhibited the PCA of MPs from both wild-type and HTF mice, suggesting that PS contributed
to the PCA.
Petersen et al. [32] reported that the association of human FVIIa to mouse TF is about three
orders of magnitude weaker than the association to human TF, whereas mouse FVIIa binds
with high affinity to both mouse and human TF. This result has led to the notion that human
FVIIa cannot be used to measure the PCA of mouse TF. However, FX activation by 10 nM of
mouse FVIIa on mouse TF-expressing cells was only 2-fold higher that that observed with 10
nM of human FVIIa [32]. In our study, we found that human FVIIa generated 6-fold less FXa
with mouse TF-positive MPs than the level of FXa generated with mouse FVIIa. Our data
indicate that human FVIIa can be used to measure MP TF activity in mouse plasma, albeit with
a slightly reduced sensitivity compared with mouse FVIIa.
In conclusion, measurement of the PCA of MPs should be performed in the presence and
absence of an inhibitory anti-mouse antibody to distinguish TF-dependent vs. TF-independent
PCA. We found that levels of MP TF activity but not PS-positive MPs correlated with TAT,
which indicates that TF-positive MPs are a better biomarker for thrombosis risk than total MPs
in a mouse model of endotoxemia.
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Lipopolysaccharide (LPS) increases levels of microparticles (MP), MP procoagulant activity
(PCA) and TAT in wild-type mice. Wild-type C57/B6J mice were given an intraperitoneal
injection of either phosphate-buffered saline (PBS) or LPS and blood was collected after 6 h.
(A) Total MP PCA was measured using mouse factor (F)VIIa and human FX in the presence
of rat IgG (white bars) or 1H1 (black bars). (B) MP tissue factor (TF) activity was calculated
by subtraction of the MP PCA generated in the presence of 1H1 from the total MP PCA
generated in the presence of IgG control. (C) Levels of TAT in the plasma from mice treated
with PBS (white bar) or LPS treated (black bar). (D) The number of PS-positive MPs in plasma
from mice treated with PBS (white bar) or LPS (right bar) is shown. All results are shown as
mean ± SD, n = 4–6 mice per group. Asterisks indicate statistically significant differences
between the groups.
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Measurement of microparticle (MP) procoagulant activity (PCA) in wild-type mice using
mouse or human factor (F)VIIa. Total MP PCA in plasma from wild-type mice treated with
either phosphate-buffered saline (PBS) control (left bars) or lipopolysaccharide (LPS) (right
bars) was measured using either human FVIIa (white bars) or mouse FVIIa (black bars) and
human FX. The inset is an enhanced plot of the PBS control. Data are shown as mean ± SD
(n = 5). Asterisks indicate a statistically significant difference between the MP PCA observed
with human FVIIa.
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Species-specific inhibition of microparticle (MP) procoagulant activity (PCA) from wild-type
and human TF (HTF) mice. (A and B) Total MP PCA in plasma from wild-type mice treated
with either phosphate-buffered saline (PBS) control (left bars) or lipopolysaccharide (LPS)
(right bars) was measured using human factor (F)VIIa and human FX in the presence of 1H1
or isotype IgG or HTF-1 or isotype IgG. Data are shown as mean ± SD (n = 6–7). (C and D)
Total MP PCA in plasma from HTF mice treated with either PBS control (left bars) or LPS
(right bars) was measured using human FVIIa and human FX in the presence of 1H1 or isotype
IgG or HTF-1 or isotype IgG. Data are shown as mean ± SD (n = 4). Asterisks indicate
statistically significant differences between the groups.
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Effect of human factor (F)VIIai and annexin V on microparticle (MP) procoagulant activity
(PCA) from wild-type and human TF (HTF) mice. (A) Total PCA in MPs isolated from plasma
of wild-type mice treated with either phosphate-buffered saline (PBS) control (white bar) or
lipopolysaccharide (LPS) (black bars) was measured using mouse FVIIa and human FX in the
presence of 1H1, isotype IgG, human FVIIai or annexin V. (B) Total MP PCA from plasma
of HTF mice treated with either PBS control (white bar) or LPS (black bars) was measured
using human FVIIa and human FX in the presence of HTF-1, isotype IgG, human FVIIai or
annexin V. Data are shown as mean ± SD (n = 4). Asterisks indicate statistically significant
differences relative to the IgG control.
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Levels of microparticle (MP) procoagulant activity (PCA), MP tissue factor (TF) activity, TAT
and MPs in human TF (HTF) and Low TF Mice. Total MP PCA (A) and MP TF activity (B)
in plasma from HTF and low mice treated with either PBS control (white bars) or LPS (black
bars) was measured using human FVIIa and human FX. TF activity in the MPs was determined
using HTF-1. Data are shown as mean ± SD (n = 4–5). (C) Levels of TAT in the plasma from
HTF (left bars) and low TF (right bars) mice treated with phosphate-buffered saline (PBS)
(white bars) or lipopolysaccharide (LPS)-treated (black bars). (D) Number of PS-positive MPs
in plasma from HTF mice (left bars) and low TF mice (right bars). All results are shown as
mean ± SD, (n = 4–6). Asterisks indicate statistically significant differences between the
groups.
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Levels of microparticle (MP) tissue factor (TF) activity correlate with levels of TAT. A
significant linear correlation was observed between levels of MP TF activity and TAT in
endotoxemic wild-type mice (R = 0.78, P < 0.01, n = 16).
WANG et al. Page 14
J Thromb Haemost. Author manuscript; available in PMC 2010 March 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
